Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 54Leukemia, B-Cell 7Lymphoma, Mantle-Cell 5Leukemia 5Lymphoma 4Lymphoma, Non-Hodgkin 3Lymphoma, Large B-Cell, Diffuse 3Recurrence 2Leukemia, Prolymphocytic 2Hematologic Neoplasms 2Waldenstrom Macroglobulinemia 1Multiple Myeloma 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Lymphatic Diseases 1Leukemia, Hairy Cell 1Hodgkin Disease 1Heart Failure 1Glioblastoma 1Chromosome 17 deletion 1Burkitt Lymphoma 1Anemia, Hemolytic, Autoimmune 1

Interventions

venetoclax 6fludarabine phosphate 5ibrutinib 3Peripheral Blood Stem Cell Transplantation 3Melphalan 3fludarabine 2Whole-Body Irradiation 2Tacrolimus 2Mycophenolic Acid 2pirtobrutinib 1pembrolizumab 1obinutuzumab 1carmustine, poliferprosan 20 drug combination 1acalabrutinib 1Sirolimus 1Nivolumab 1Maintenance 1Etoposide 1Dexamethasone 1Cytarabine 1Cyclosporins 1Cyclosporine 1Cyclophosphamide 1Carmustine 1Bortezomib 1Bendamustine Hydrochloride 1Atorvastatin 1Alemtuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Chromosome 17 deletion × acalabrutinib × Other hematologic neoplasm × Clear all
NCT02337829 2026-01-08

Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL

Acerta Pharma BV

Phase 2 Completed
48 enrolled 12 charts
LymphoidOther hematologic neoplasm

Chromosome 17 deletion, Leukemia, Lymphoma, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡